Literature DB >> 376935

[Monitoring of remission quality in acute leukemia of childhood by repeated determinations of B-cell-allo-antigen on lymphoblasts (author's transl)].

H U Schwenk, U Schneider.   

Abstract

B-Cell-allo-antigen was demonstrated on lymphoblasts of children with acute lymphoblastic leukemia and on 14 permanent growing lymphoblastoid cell-lines. Pooled sera of 4 selected multiparas and a rabbit antiserum were used as specific antisera. Antigen was more effectively detected with heterologous antibodies than with human antisera. Primary lymphoblasts were characterized by B-cell-allo-antigen and lack of membrane immunoglobulins and Fc-receptors on the same cell. The quality of remission, i.e. the early diagnosis of relapse was better surveyed by immunological characterization than by cytological assessment. The bone marrow was examined in 8 patients with initial leukemia, in 13 patients with partial remission and in 30 patients in complete hematological remission. A striking discrepancy between immunological and cytological examination was observed in the bone marrow 4 weeks after inital anti-leukemic chemotherapy. At that time an increased number of blast-typed cells could still be counted in the immunological evaluation, although the cytological evaluation revealed already a complete hematological remission.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 376935     DOI: 10.1007/bf01477500

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  20 in total

1.  ENZYMATIC DIGESTION OF RABBIT GAMMA GLOBULIN AND ANTIBODY AND CHROMATOGRAPHY OF DIGESTION PRODUCTS.

Authors:  A NISONOFF
Journal:  Methods Med Res       Date:  1964

2.  Purification and structural characterisation of human HLA-linked B-cell antigens.

Authors:  T A Springer; J F Kaufman; C Terhorst; J L Strominger
Journal:  Nature       Date:  1977-07-21       Impact factor: 49.962

3.  Membrane phenotyping: diagnosis, monitoring and classification of acute 'lymphoid' leukaemias.

Authors:  M F Greaves; G Janossy; M Roberts; N T Rapson; R B Ellis; J Chessels; T A Lister; D Catovsky
Journal:  Haematol Blood Transfus       Date:  1977

4.  The dynamic state of the lymphocyte membrane. Factors affecting the distribution and turnover of surface immunoglobulins.

Authors:  F Loor; L Forni; B Pernis
Journal:  Eur J Immunol       Date:  1972-06       Impact factor: 5.532

5.  Simultaneous disparity of bone marrow specimens in acute leukemia.

Authors:  R B Raney; C W McMillan
Journal:  Am J Dis Child       Date:  1969-05

6.  Conjugation of antibodies with fluorochromes: modifications to the standard methods.

Authors:  J W Goding
Journal:  J Immunol Methods       Date:  1976       Impact factor: 2.303

7.  The H-2 major histocompatibility complex and the I immune response region: genetic variation, function, and organization.

Authors:  D C Shreffler; C S David
Journal:  Adv Immunol       Date:  1975       Impact factor: 3.543

8.  [Early diagnosis of leukaemic transformation of malignant non-hodgkin lymphoma in childhood (author's transl)].

Authors:  H U Schwenk; G Willital
Journal:  Dtsch Med Wochenschr       Date:  1976-03-19       Impact factor: 0.628

9.  L-Asparaginase, vincristine, and prednisone for induction of first remission in acute lymphocytic leukemia.

Authors:  J A Ortega; M E Nesbit; M H Donaldson; R E Hittle; J Weiner; M Karon; D Hammond
Journal:  Cancer Res       Date:  1977-02       Impact factor: 12.701

10.  Evidence for identity or close association of the Fc receptor of B lymphocytes and alloantigens determined by the Ir region of the H-2 complex.

Authors:  H B Dickler; D H Sachs
Journal:  J Exp Med       Date:  1974-09-01       Impact factor: 14.307

View more
  2 in total

1.  Classification of normal and malignant lymphatic cells using acid phosphatase and acid esterase.

Authors:  D Huhn; E Thiel; H Rodt
Journal:  Klin Wochenschr       Date:  1980-01-15

2.  Binding of lectins to leukemic cell lines.

Authors:  H U Schwenk; U Schneider; K H Herzog
Journal:  Blut       Date:  1980-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.